Doyle Anthony
- SEC CIK
- 0001808688
No open-market purchases or sales filed in the past year.
Current role at each company
- BCRX Biocryst Pharmaceuticals IncChief Financial Officeras of Dec 23, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Doyle Anthony as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 15, 2024 (view filing) | May 14 | 1 day | Doyle AnthonyChief Financial Officer | PPurchase | +36.3K | $5.57 | +$202.2K | +15.8%266.7K after | |
| Dec 19, 2022 (view filing) | Dec 15 | 4 days | Doyle AnthonyChief Financial Officer | SSale | −5.70K | $10.90 | −$62.1K | −3.4%164.0K after | |
| Nov 24, 2021 (view filing) | Nov 23 | 1 day | Doyle AnthonyChief Financial Officer | PPurchase | +35.3K | $12.48 | +$440.0K | +60.3%93.7K after |